TickerFiles

Allogene Therapeutics, Inc. 10-K filing

Filed 2026-03-12 · Report date 2025-12-31 · 2025 FY

View Original SEC Filing

Filing metadata

Accession number
0001628280-26-017242
Form type
10-K
CIK
0001737287
Primary document
https://www.sec.gov/Archives/edgar/data/1737287/000162828026017242/allo-20251231.htm

Extracted primary information

This filing includes deterministic financial metrics extracted from public filing data for Allogene Therapeutics, Inc..

Reported financial metrics

MetricCurrentPriorChange
Revenue$0--
Operating Income$-209.3M--
Net Income$-190.9M--
Eps Basic-0.87--
Eps Diluted-0.87--
Cash And Equivalents$51.7M--
Total Assets$415.9M--
Total Liabilities$123.4M--
Shareholders Equity$292.5M--
Operating Cash Flow$-149.2M--
Capital Expenditures$386,000--